Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000702 | 0.89 | MAPT (0.45) | MAPTALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL14091319 | 0.87 | MAPT (0.55) | MAPTALDH1A1KDM4EHPGDNPC1 | |
| SCHEMBL5003010 | 0.86 | KMT2A (0.39) | MAPTALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL4997409 | 0.83 | L3MBTL1 (0.52) | MAPTALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL4992856 | 0.82 | TP53 (0.50) | MAPTALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL5000659 | 0.80 | PKM (0.41) | MAPTALDH1A1KDM4ETP53MAPK1 | |
| SCHEMBL4993132 | 0.78 | MAPT (0.55) | MAPTALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL4995211 | 0.77 | MEN1 (0.46) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL5000912 | 0.77 | RBP4 (0.47) | MAPTALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL4996131 | 0.76 | FYN (0.43) | MAPTALDH1A1HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | MAPT 5/4885ALDH1A1 1034/4885KDM4E 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.